Hypertension in pregnancy is defined as a systolic blood pressure of ≥140 mmHg or a diastolic blood pressure of ≥90 mmHg, or both, based on at least 2 measurements ≥4 hours apart.
Diagnosis of severe hypertension is made when blood pressure is ≥160/110 mmHg.
Measurement should be repeated after 15 minutes for confirmation of severe hypertension.

Hypertension%20in%20pregnancy Management


Chronic Hypertension or Gestational Hypertension 

  • Poorly controlled hypertension warrants weekly clinic appointments; if well controlled, it may be every 2-4 weeks  

Maternal Monitoring 

  • In each physician visit, patients should be observed closely for early signs of preeclampsia
  • Antihypertensive treatment should be started if severe hypertension develops before term
  • Women with high-risk chronic hypertension are more likely to have adverse maternal and perinatal complications
    • Maternal risks include disseminated vascular coagulation, placental abruption, stroke and multiple organ failure involving the kidney and the liver 
    • Perinatal loss and neonatal complications may occur in women with renal insufficiency (serum creatinine >1.4 mg/dL), DM with vascular involvement, severe collagen vascular disease, cardiomyopathy or coarctation of the aorta
    • Other potential maternal outcomes are congestive heart failure, acute renal failure requiring dialysis, or death

Fetal Monitoring 

  • Ultrasound for assessment of fetal growth and amniotic fluid volume, and umbilical artery Doppler velocimetry may be done in women with chronic hypertension at 28, 32 and 36 weeks and with gestational hypertension at diagnosis and repeated every 2-4 weeks if normal 
  • Cardiotocography may be done only if clinically indicated


Maternal Monitoring 

  • Purpose is to observe progression of the condition both to prevent maternal complications during delivery and to assess fetal well-being
  • Monitor BP twice weekly
  • Order lab tests as in diagnosis of preeclampsia done weekly: CBC, platelet count, liver enzymes, LDH, uric acid, creatinine
  • Assess for proteinuria weekly
  • Invasive hemodynamic monitoring may be required
    • Monitor fluid volume expansion especially in cases of pulmonary edema, persistent oliguria unresponsive to fluid challenge, intractable severe hypertension and in delivery with epidural anesthesia

Fetal Monitoring 

  • With preeclampsia, risk of fetal prematurity or preterm birth, intrauterine growth retardation and intrauterine death are high 
  • Do nonstress test (NST) twice weekly
  • Determine amniotic fluid index (AFI) once or twice weekly
  • Biophysical profile (BPP) weekly may replace one of the twice-weekly NSTs and AFIs
  • Ultrasound examination of the fetus to assess fetal growth and an umbilical artery Doppler velocimetry should be done every 2-4 weeks
  • Cardiotocography may be done at diagnosis of preeclampsia or severe gestational hypertension but may be repeated only if clinically indicated
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Jun 2020

Achieving standard of care targets, such as reduced levels of low-density lipoprotein cholesterol and glycated haemoglobin, improves outcomes in coronary heart disease patients, a new study has found.

Pearl Toh, 19 Jan 2018
Blood pressure (BP) control can be best achieved with a multilevel, multicomponent approach involving team-based care with physician- and non-physician-led interventions, as well as patient-level strategies, according to findings of a meta-analysis.
Dr. Joseph Delano Fule Robles, 24 Jul 2018

Functional foods benefit the body beyond its nutritional effects, with studies showing that they can improve general state of health and reduce the risk of diseases.

29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.